Osteoarthritis of Knee
Conditions
Keywords
Osteoarthritis of knee, Glucosamine sulfate, Chondroitin sulfate
Brief summary
This phase III clinical study will be conducted in Brazilian research sites. It will be included in the study 314 participants diagnosed with primary knee OA according to the classification criteria of the ACR. After a washout period, the participants will be randomized to receive the combination of glucosamine sulfate + chondroitin sulfate of bovine origin of Eurofarma Laboratorios S.A. (N= 157) or the combination of glucosamine sulfate + chondroitin sulfate of Zodiac Pharmaceuticals S.A. Condroflex ® (N = 157). The treatment period of the study will be of 24 weeks. Each participant will perform seven visits to the research site. The main evaluations will be the improve of pain in the target knee by questionnaire Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and quality of life by SF-12 questionnaire.
Interventions
DRUGGlucosamine and chondroitin sulfate combination (Eurofarma)
DRUGGlucosamine and chondroitin sulfate combination (Zodic)
Sponsors
Eurofarma Laboratorios S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Male and female patients meeting all the following criteria will be enrolled in the study: 1. Aged ≥ 40 years. 2. Clinical and radiological diagnosis of primary (idiopathic) arthrosis of knee according to the criteria of the American College of Rheumatology (ACR). 3. Kellgren and Lawrence radiological classification of degree 2 or 3 in x-ray of knee-target obtained in 3 months prior to the screening visit of the study. 4. Presence of painful symptoms in the target knee in the last 3 months due to osteoarthritis. 5. Visual analogue scale for evaluation of the pain of osteoarthritis of knee by the research participant in the screening visit ≥ 40 mm 6. Average score ≥ 40 mm in the subscale of pain (from 0 to 100 mm) in the target knee of the questionnaire Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), in the randomization visit. 7. Functional class ACR from I to III. 8. Signing the Informed Consent Form (ICF) before the performance of any study procedure.
Exclusion criteria
Patients meeting at least one of the following criteria will be excluded from the study: 1. Diagnosis of septic arthritis, inflammatory arthritis (as rheumatoid arthritis), gout, pseudogout, Paget's disease, dysplasias or congenital joint abnormalities. 2. Presence of inflammatory signals (edema, erythema or joint effusion) in the target knee, considered to be clinically significant by investigator. 3. Serious target knee joint misalignment, defined by investigator. 4. Predominantly patellofemoral Osteoarthritis in the target knee. 5. Historical of severe trauma or surgery (including arthroscopy) in the target knee in the 6 months before the screening visit. 6. Planned Surgery to the target knee 7. Symptomatic Osteoarthritis of the ipsilateral hip. 8. Use of non-steroidal anti-inflammatory, dipyrone and opioid analgesics or narcotics from the screening visit, or a washout period for these medicines less than those defined by the Protocol, before the randomization visit . 9. Oral Glucocorticoids, intravenously or intramuscularly in the 30 days prior to the screening visit. 10. Intraarticular corticosteroid Injection and/or hyaluronic acid in the target knee in 6 months prior to the screening visit. 11. Use of the following drugs in the periods described below, before the screening visit: 1. Diacerein, chloroquine or soybean and avocado unsaponifiables extracts in the last 3 months. 2. Duloxetine hydrochloride in the last 30 days. 3. Glucosamine Sulphate and/or chondroitin sulfate in the last 6 months. 4. Strontium ranelate for the past 6 months. 12. Historical of allergy or intolerance to treatment of the study or to paracetamol. 13. Physiotherapy or irregular practice of physical activity beginning in the 3 months prior to the screening visit. 14. Diagnosis of fibromyalgia, collagenosis or significative vascular/neurologica diseases in lower limbs that may confuse the analysis of the study. 15. Body mass index ≥ 40 kg/m2. 16. Need to use cane, crutches or a walker. 17. Presence of infectious hepatitis active or history of hepatitis medicinal products. 18. Results of ALT, AST and total bilirubin and fractions above the upper limit of normal. 19. Serum creatinine level above the upper limit of normal. 20. Fasting blood glucose \> 110 mg/dL or glycated hemoglobin \> 6.5%. 21. Use of anticoagulants. 22. Consumption of alcohol more than one dose a day (women) or two doses a day (men). 23. Presence of serious diseases or not controlled. 24. Planned surgery to occur during the period of participation in the study. 25. Presence of pregnancy or breastfeeding. 26. Women of childbearing potential must agree to use highly effective contraception. 27. Participation in a clinical trial protocol within the previous 12 months unless, at the investigator's discretion, his or her participation may imply a direct benefit for the participant. 28. Presence of any condition which, at the investigator's discretion, may consider the participation of the patient inadequate for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute change of pain WOMAC subscale score 24 weeks after initiation of treatment. | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Absolute change the overall assessment of the disease by the investigator along treatment as measured by Visual Analog Scale from 0 to 100mm. | 24 weeks |
| Absolute change score of physical and mental components of the questionnaire SF-12 24 weeks after initiation of treatment compared to baseline. | 24 weeks |
| Incidence and profile of adverse events coded as MedDRA by treatment group. | 24 weeks |
| Frequency of treatment discontinuation for adverse events and laboratory abnormalities. | 24 weeks |
Countries
Brazil
Outcome results
None listed